MAP
AXSM icon

Moody Aldrich Partners’s Axsome Therapeutics AXSM Stock Holding History

Moody Aldrich Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$406K Sell
1,660
-32,313
-95% -$7.01M 0.07% 136
2026
Q1 		$5.74M Sell
33,973
-6,300
-16% -$1.09M 1.04% 28
2025
Q4 		$7.36M Sell
40,273
-11,203
-22% -$1.56M 1.37% 9
2025
Q3 		$6.25M Sell
51,476
-9,934
-16% -$1.12M 1.19% 17
2025
Q2 		$6.41M Sell
61,410
-929
-1% -$98.4K 1.24% 23
2025
Q1 		$7.27M Buy
62,339
+17,201
+38% +$1.96M 1.52% 16
2024
Q4 		$3.82M Sell
45,138
-15,506
-26% -$1.43M 0.71% 68
2024
Q3 		$5.45M Sell
60,644
-1,107
-2% -$96.6K 0.99% 39
2024
Q2 		$4.97M Sell
61,751
-3,908
-6% -$289K 0.97% 37
2024
Q1 		$5.24M Sell
65,659
-1,207
-2% -$101K 0.89% 41
2023
Q4 		$5.32M Sell
66,866
-6,767
-9% -$452K 0.96% 40
2023
Q3 		$5.15M Buy
73,633
+8,940
+14% +$668K 0.98% 37
2023
Q2 		$4.65M Buy
64,693
+32,114
+99% +$2.37M 0.9% 42
2023
Q1 		$2.01M Sell
32,579
-19,567
-38% -$1.29M 0.41% 90
2022
Q4 		$4.02M Sell
52,146
-70,115
-57% -$4.19M 0.82% 55
2022
Q3 		$5.46M Buy
122,261
+79,721
+187% +$3.98M 1.12% 31
2022
Q2 		$1.63M Buy
+42,540
New +$1.35M 0.32% 91
2022
Q1 		– Sell
-42,871
Closed -$1.62M – 154
2021
Q4 		$1.62M Sell
42,871
-8,023
-16% -$295K 0.23% 103
2021
Q3 		$1.68M Buy
50,894
+6,914
+16% +$269K 0.21% 101
2021
Q2 		$2.97M Sell
43,980
-585
-1% -$35.1K 0.42% 85
2021
Q1 		$2.52M Buy
44,565
+952
+2% +$67K 0.36% 87
2020
Q4 		$3.55M Sell
43,613
-75
-0.2% -$5.61K 0.57% 79
2020
Q3 		$3.11M Buy
43,688
+13,512
+45% +$1.05M 0.65% 72
2020
Q2 		$2.48M Sell
30,176
-32,030
-51% -$2.47M 0.53% 76
2020
Q1 		$3.66M Buy
62,206
+17
+0% +$1.39K 1.1% 32
2019
Q4 		$6.43M Sell
62,189
-10,896
-15% -$440K 1.32% 19
2019
Q3 		$1.48M Buy
73,085
+1,510
+2% +$38.8K 0.39% 84
2019
Q2 		$1.84M Buy
+71,575
New +$1.43M 0.47% 79

Other funds holding AXSM

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TAM
Tealwood Asset Management Minneapolis, Minnesota $261M AUM 52.68% 1-Year Est. Return
CA
Cannon Advisors Charlotte, North Carolina $164M AUM 30.34% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

Moody Aldrich Partners's AXSM Position: Q2 2026 in Review

Moody Aldrich Partners reduced its Axsome Therapeutics (AXSM) stake by 95% in Q2 2026, selling an estimated $7.01M and leaving 1,660 shares worth $406K. The position accounts for 0.07% of the portfolio, ranked #136.

Moody Aldrich Partners first reported a position in AXSM in Q2 2019 and has held it in 28 quarters since. The position peaked at $7.36M in Q4 2025. 38 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Moody Aldrich Partners held 1,660 shares of Axsome Therapeutics worth $406K as of Q2 2026.
  • Moody Aldrich Partners sold 32,313 Axsome Therapeutics shares in Q2 2026, an estimated $7.01M.
  • Axsome Therapeutics made up 0.07% of Moody Aldrich Partners's portfolio in Q2 2026, its #136 holding.
  • Moody Aldrich Partners first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • Moody Aldrich Partners's Axsome Therapeutics position peaked at $7.36M in Q4 2025.
  • 38 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.